Physician profile
Fernando Silva
NPI 1558777425
$13,643.10
in general payments reported to CMS, 2019-2025
69 companies · $4,130 in 2025
The $4,130 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $625 · 2022: $959 · 2023: $3,508 · 2024: $4,421 · 2025: $4,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $1,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,932.11 |
| Education | $1,126.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $899.29 | 2021-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $848.03 | 2023-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $800.21 | 2021-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $741.14 | 2022-2025 | Kisqali, Piqray |
| Incyte Corporation | $737.47 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Pfizer INC. | $679.76 | 2022-2025 | |
| Janssen Biotech, INC. | $675.93 | 2022-2025 | Tecvayli, Darzalex, Talvey |
| Celgene Corporation | $663.82 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Daiichi Sankyo INC. | $480.74 | 2023-2025 | Enhertu, Injectafer |
| Abbvie INC. | $468.82 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $452.99 | 2021-2025 | Enhertu, Imfinzi, Calquence |
| Takeda Pharmaceuticals U.S.A., INC. | $445.72 | 2022-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Astellas Pharma US INC | $364.23 | 2021-2025 | Padcev, Xtandi, Xospata |
| Glaxosmithkline, LLC. | $360.07 | 2021-2025 | Ojjaara, Benlysta, Zejula |
| Seagen INC. | $323.78 | 2021-2023 | Tukysa, Adcetris, Padcev |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $301.73 | 2022-2025 | |
| Lilly USA, LLC | $255.86 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $228.76 | 2021-2025 | |
| Ipsen Biopharmaceuticals, INC | $212.28 | 2025 | Onivyde |
| Beigene USA, INC. | $192.34 | 2021-2024 | Brukinsa |
| Jazz Pharmaceuticals INC. | $178.47 | 2021-2025 | |
| Dendreon Pharmaceuticals LLC | $176.20 | 2021-2025 | Provenge |
| Amgen INC. | $168.77 | 2021-2023 | Lumakras, Vectibix, Nplate |
| Stemline Therapeutics INC. | $155.15 | 2023-2025 | Orserdu |
| Array Biopharma INC | $149.23 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Genentech USA, INC. | $143.01 | 2022-2025 | Alecensa, Tecentriq, Phesgo |
| Eisai INC. | $135.16 | 2021-2025 | |
| Kite Pharma, INC. | $121.63 | 2023-2025 | Yescarta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.12 | 2022-2025 | Gilotrif |
| Servier Pharmaceuticals LLC | $112.43 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $110.63 | 2023 | Imbruvica |
| Deciphera Pharmaceuticals INC. | $109.94 | 2021-2025 | Qinlock, Romvimza |
| Regeneron Healthcare Solutions, INC. | $106.26 | 2025 | Libtayo |
| Genzyme Corporation | $103.75 | 2021-2023 | |
| Karyopharm Therapeutics INC. | $102.85 | 2023-2025 | Xpovio |
| Emd Serono, INC. | $98.95 | 2023-2025 | Bavencio |
| Beone Medicines USA, INC. | $95.82 | 2025 | Brukinsa |
| Sanofi-Aventis U.S. LLC | $95.00 | 2023 | |
| Puma Biotechnology, INC. | $94.65 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $91.22 | 2023-2024 | Tavalisse, Rezlidhia |
| Blueprint Medicines Corporation | $80.42 | 2022-2025 | Ayvakit |
| Taiho Oncology, INC. | $80.31 | 2024-2025 | |
| Syndax Pharmaceuticals, INC. | $74.94 | 2025 | |
| Legend Biotech USA INC. | $72.27 | 2024-2025 | Carvykti |
| Aveo Pharmaceuticals, INC. | $59.57 | 2022-2024 | Fotivda |
| Genmab U.S., INC. | $57.23 | 2023-2025 | Epkinly |
| Morphosys, US INC. | $55.55 | 2023 | Monjuvi |
| Foundation Medicine, INC. | $54.33 | 2023 | |
| Myriad Genetic Laboratories, INC. | $52.84 | 2021-2025 | Myrisk |
| Pharmacosmos Therapeutics INC. | $50.21 | 2023-2025 | Monoferric |
| Geron Corporation | $49.29 | 2025 | Rytelo |
| Pharmaessentia USA Corporation | $29.74 | 2024 | Besremi |
| Alexion Pharmaceuticals, INC. | $29.10 | 2024 | Ultomiris |
| Csl Behring | $27.37 | 2025 | Hizentra |
| Tersera Therapeutics LLC | $25.47 | 2022 | |
| G1 Therapeutics, INC. | $22.04 | 2023 | Cosela |
| Adaptive Biotechnologies Corporation | $21.51 | 2024 | Clonoseq |
| Recordati_rare_diseases_inc. | $21.22 | 2025 | Sylvant |
| Exelixis INC. | $20.68 | 2024 | Cabometyx |
| Menarini Silicon Biosystems, INC. | $20.03 | 2025 | |
| Alnylam Pharmaceuticals INC. | $18.48 | 2023 | Givlaari |
| Sumitomo Pharma America, INC. | $18.46 | 2025 | Orgovyx |
| Mirati Therapeutics, INC. | $18.18 | 2023 | Krazati |
| Tg Therapeutics, INC. | $17.78 | 2022 | |
| Iovance Biotherapeutics, INC. | $16.55 | 2024 | Amtagvi |
| Agios Pharmaceuticals, INC. | $16.23 | 2023 | Pyrukynd |
| Acrotech Biopharma INC. | $13.60 | 2023 | Beleodaq |
| Myovant Sciences INC. | $12.89 | 2022 | |
| Amag Pharmaceuticals, INC. | $11.60 | 2021 |
Drugs and devices associated with these payments
Keytruda $821Enhertu $586Reblozyl $445Opdivo $422Jakafi $413Monjuvi $314Imbruvica $308Trodelvy $285Lynparza $277Brukinsa $234Padcev $219Venclexta $206Xtandi $200Jaypirca $186Ojjaara $186Kisqali $178Pluvicto $176Inlyta $164Provenge $163Doptelet $163Tecvayli $156Nubeqa $156Orserdu $155Zepzelca $154Verzenio $154Darzalex $150Braftovi $149Tukysa $149Epkinly $142Adcetris $140Ninlaro $137Talvey $136Opdualag $134Fruzaqla $127Elrexfio $127Yescarta $122Carvykti $121Talzenna $120Lenvima $119Mektovi $118Ibrance $115Imfinzi $114Lorbrena $114Jevtana $112Vonjo $107Libtayo $106Xpovio $103Scemblix $97.07Alunbrig $95.08Calquence $92.26Tavalisse $91.22Rezlidhia $91.22Welireg $87.45Rybrevant $82.16Lonsurf $80.31Inqovi $80.31Pomalyst $69.89Tibsovo $69.34Bosulif $66.12Orgovyx $66.05Gilotrif $64.42Qinlock $63.97Ayvakit $62.42Benlysta $62.08Elahere $57.76Keytruda Qlex $57.52Retevmo $57.07Tasigna $55.09Tivdak $55.02Nerlynx $54.84Paxlovid $50.94Monoferric $50.21Rytelo $49.29Tecentriq $48.36Alecensa $48.36Bavencio $47.31Erleada $46.43Promacta $46.40Piqray $46.39Idhifa $44.60Fabhalta $42.99Fotivda $42.13Zejula $41.63Myrisk $40.59Lutathera $40.39Shingrix $37.34Cablivi $36.24Enjaymo $36.24Xalkori $33.77Kadcyla $33.12Phesgo $33.12Perjeta $33.12Rozlytrek $32.87Avastin $32.87Gavreto $32.87Lumakras $32.21Stivarga $30.10Vitrakvi $30.10Besremi $29.74Onivyde $29.30
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.